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Abstract
The vasopressin-receptor antagonists have received ap-
proval for the treatment of hyponatraemia secondary to the
syndrome of inappropriate antidiuretic hormone secretion
(SIADH). It is therefore necessary that physicians encoun-
tering hyponatraemia focus onSIADH.Recent studies show
that hyponatraemia is often poorly managed—insufficient
diagnostic tests are ordered and patients are undertreated.
At the same time, it has become clear that chronic hypona-
traemia causes neurological symptoms such as gait distur-
bances and attention deficits. However, physicians often
tolerate chronic hyponatraemia as if it were benign, or as if
its treatment would cause significant morbidity. Therefore,
physicians must reconsider the diagnostic and therapeutic
approaches to hyponatraemia and SIADH.
Keywords: adrenal insufficiency; diagnosis; epidemiology; vasopressin;
vasopressin-receptor antagonists
Introduction
The recent introduction of vasopressin-receptor antago-
nists makes it imperative to revisit hyponatraemia and the
syndrome of inappropriate antidiuretic hormone secretion
(SIADH).
Selective vasopressin V2-receptor antagonists, also
called ‘vaptans’, represent the first targeted therapy for
SIADH, which is one of the most common causes of hy-
ponatraemia [1]. The various compounds are in different
stages of development and include mozavaptan [2] lixivap-
tan, satavaptan and tolvaptan [1]. Tolvaptan has recently
been approved by the European Medicines Agency for the
treatment of hyponatraemia secondary to SIADH. When
new drugs become available, the excitement about their
possibilities sometimes overshadows the disorder for which
they will be used. Because hyponatraemia is such a hetero-
geneous and complex disorder, and because tolvaptan has
been approved only for the treatment of hyponatraemia sec-
ondary to SIADH, a rational use of vasopressin-receptor
antagonists first requires a proper diagnosis of SIADH.
Therefore, may we suggest that in addition to reading the
package insert of these new drugs, read this article, in which
we will review hyponatraemia and SIADH and discuss the
potential role of vasopressin-receptor antagonists. Finally,
on a more semantic note, it was recently proposed that
SIADH should be called the syndrome of inappropriate
antidiuresis (SIAD), because vasopressin (antidiuretic hor-
mone) is not always elevated, for example in patients with
reset osmostat or with an activating mutation of the vaso-
pressin V2-receptor [1]. However, in this article we will use
the traditional term SIADH, because we focus on disorders
with elevated vasopressin.
Why does hyponatraemia matter?—The previous
concept
The more obvious answers as to why hyponatraemia is clin-
ically relevant used to be because of cerebral oedema and
the osmotic demyelination syndrome (ODS). Although rel-
atively rare, these two neurological conditions represent
the two most severe complications of hyponatraemia and
its treatment. Both can occur with any cause of hypona-
traemia, including SIADH. Cerebral oedema usually occurs
in acute hyponatraemia of moderate or severe degree (drop
in serum sodium [SNa] ≤ 125 mmol/L in ≤ 48 h). In this
setting, brain cells do not have time to adapt to extracellular
hypotonicity and cell swelling. It is a medical emergency
that, if left untreated, can lead to herniation of the brain
stem into the foramen magnum and permanent brain dam-
age [3]. ODS is not a consequence of hyponatraemia but of
its treatment. The term refers to the neurological sequelae
(e.g. sudden para or quadraparesis, dysphagia, dysarthria,
diplopia and loss of consciousness) that can develop when
chronic hyponatraemia is corrected too fast [4]. Because
the brain damage in ODS is often irreversible, iatrogenic
and preventable, it remains a concern in the management of
hyponatraemia [5]. ODS can usually be prevented, however,
by adhering to the recommended maximal correction rates
of ≤12 mmol/L/24 h and ≤18 mmol/L/48 h in chronic hy-
ponatraemia [4,6,7]. If chronic hyponatraemia is associated
with other risk factors for ODS (hypokalaemia, malnutri-
tion, alcoholism), the limit should be adjustedmore towards
8 mmol/L/24 h [8,9]. If the duration of hyponatraemia is
in doubt (acute versus chronic), computed tomography or
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magnetic resonance imaging of the brain may sometimes
help to diagnose cerebral oedema, suggesting acute
hyponatraemia.
Are there any other reasons why hyponatraemia matters?
There are also two less obvious answers to this question.
The first is that the current management of patients with
hyponatraemia is inadequate. Below, in the section entitled
‘Current management of hyponatraemia is inadequate’, we
will review three recent studies in which the clinical re-
ality of the management of hyponatraemia was studied.
Euphemistically speaking, it was found that there is con-
siderable room for improvement. For instance, the causes
of hyponatraemia were poorly studied, hyponatraemia was
undertreated, not treated at all or all of the above. The
second less obvious answer to why hyponatraemia mat-
ters relates to a landmark study by Renneboog and col-
leagues [10]. They demonstrated that chronic and appar-
ently asymptomatic mild-to-moderate hyponatraemia is not
as innocent as it seems. We shall address these issues later
in this article (section ‘Asymptomatic hyponatraemia is not
asymptomatic—the new concept’).
Most physicians have learned to deal with the extremes
regarding hyponatraemia. They infuse hypertonic saline in
a patient with acute hyponatraemia who has a seizure,
and hypotonic saline in a patient with chronic hypona-
traemia whose SNa is rising too fast. Therefore, it is
probably this much larger group of patients with mild-
to-moderate chronic hyponatraemia and subtle neurolog-
ical symptoms who receive suboptimal care. It appears
that they deserve better medical attention and improved
care.
Current management of hyponatraemia is
inadequate
To talk about improving themanagement of hyponatraemia,
we first need to know where we stand at present. Three
recent studies of hyponatraemia, including in patients with
SIADH, give a clear albeit worrisome picture. They show
that hyponatraemia at present is missed, misdiagnosed or
undertreated.
Gill and colleagues conducted a prospective case-control
study in 104 patients who had a SNa < 125 mmol/L. They
were then compared to random normonatraemic controls
[11]. Cases had longer hospital stays (16 ± 12 versus 13 ±
11 days) and a higher mortality rate (28% versus 9%). In
terms of underlying diseases, cases more often had pneu-
monia, alcohol abuse, neurological disease and renal in-
sufficiency, or were on therapies including thiazides, loop
diuretics and selective serotonin reuptake inhibitors. Half of
the cases had a further drop in SNa in the course of the hos-
pital treatment. These patients with ‘hospital-aggravated’
hyponatraemia more often were on diuretics (18% versus
2%). They also had a higher mortality rate (34% versus
16%) compared to hyponatraemic patients without a fur-
ther decrease in SNa. In some of these cases, iatrogenic
factors (hypotonic intravenous fluids) or missed diagnoses
(primary adrenal insufficiency) were identified. In 73% of
cases, no plausible explanation for hyponatraemia had been
documented in the charts. The study did not report details of
any treatment of hyponatraemia, but the average discharge
SNa was reported to be 131 ± 7 mmol/L, suggesting that
hyponatraemia was not corrected fully in a sizeable portion
of patients.
In a second study, Clayton and colleagues performed
a retrospective analysis of 108 patients with a SNa ≤
125 mmol/L [12]. Neurological symptoms, including un-
steadiness of gait and falls, were found to be present upon
admission in 36% of patients. The majority of patients
(75.3%) had a multifactorial cause of hyponatraemia, of
which diuretics, congestive heart failure and liver cirrho-
sis were the most common. The high mortality rate (20%
during hospital stay, 45% after a follow-up of 11/2 years)
was mainly ascribed to the severity of the underlying dis-
eases (usually heart and liver failure). Perhaps most re-
vealing were the diagnostic shortcomings. Serum glucose
was ordered in 70%, serum osmolality in 61%, urine os-
molality in 47%, urine sodium in 40%, thyroid function
in 49% and adrenal function in 15%. None of the 48% of
patients in whom SIADH was suspected met established
diagnostic criteria, usually because insufficient tests were
ordered. Why these parameters are important in the diagno-
sis of hyponatraemia and SIADH will be discussed in more
detail in the next section (How to diagnose SIADH reli-
ably?). This study did not report details on the treatment of
hyponatraemia.
A third study was published by our own group [13].
It corroborated most of the above findings. Thirty-eight
patients who had hyponatraemia on admission (SNa 121 ±
4mmol/L) were compared to 36 patients who developed hy-
ponatraemia in the hospital (SNa 133 ± 5 to 122 ± 4 mmol/
L in ∼7 days). Neurological symptoms (e.g. sensorium
changes, seizures) were frequent in all (in 40% of ad-
mission hyponatraemia and in 33% of hospital-acquired
hyponatraemia). Similar to the study by Clayton et al.,
hyponatraemia was often multifactorial. In patients with
hospital-acquired hyponatraemia, the number of factors
predisposing to hyponatraemia was increased from 1.7 ±
1.5 to 3.3± 1.6 during hospitalization, suggesting that these
patientswere sicker. The factors included thiazides, surgery,
hypotonic intravenous fluids and vasopressin-stimulating
drugs. The duration of hospitalization was similar to that
reported by Gill et al. (18.2 ± 11.5 days), but patients
with hospital-acquired hyponatraemia were hospitalized for
longer (30.7 ± 23.4 days). It was also found that hypona-
traemia was frequently not documented in the charts (in
42% of admission hyponatraemia, and in 69% of hospital-
acquired hyponatraemia). In cases where treatment was
given for hospital-acquired hyponatraemia, therapy was de-
layed. Patients who did not receive therapy for hypona-
traemia had significantly higher mortality rates (37 versus
13%).
Together these studies illustrate the current shortcom-
ings in the diagnosis and management of hyponatraemia.
The diagnostic work-up for patients with hyponatraemia
is often insufficient and risking misdiagnosis and subse-
quent mismanagement. Patients whose hyponatraemia de-
velops or worsens in hospital have poorer outcomes, and
there is a possibility that hyponatraemia contributed to the
outcome.
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Table 1. Diagnostic criteria for SIADH
Essential features
• Decreased effective serum osmolality (<275 mOsm/kg)
• Urinary osmolality >100 mOsm/kg during hypotonicity of the serum
• Clinical euvolaemia
• Urinary sodium >40 mmol/L with normal dietary salt intake
• Normal thyroid and adrenal function
• No recent use of diuretics
Supplemental features
• Serum uric acid <0.24 mmol/L
• Serum urea <3.6 mmol/L, low normal serum creatinine
• Fractional sodium excretion >1%, fractional urea excretion >55%
• Failure to correct hyponatraemia after 0.9% saline infusion
• Correction of hyponatraemia through fluid restriction
• Abnormal water loading test (excretion <80% of a 20 mL/kg water
load in 4 h)
• Elevated vasopressin levels despite hypotonicity and clinical
euvolaemiaa
Adapted from Schwartz et al. [15], Janicic and Verbalis [14] and Ellison
and Berl [1].
aDuring hyponatraemia, a measurable vasopressin level should be in-
terpreted as too high, because under normal circumstances vasopressin
should be suppressed.
Table 2. How to diagnose SIADH?
• Determine the bare minimum: serum and urine sodium and
osmolality
• Find a low serum osmolality, high urine sodium (>40 mmol/L) and
osmolality (>100 mOsm/kg, often > serum osmolality)
• Find serum uric acid, urea and/or creatinine levels that are low or low
normal
• Assess the extracellular fluid volume, but do not make it a decisive
parameter
• Exclude diuretic use, hypothyroidism, and adrenal insufficiency (low
threshold for performing the Synacthen test)
• When unsure, assess the response in serum sodium to intravenous
isotonic saline
How to diagnose SIADH reliably?
The generally accepted criteria for SIADH include a num-
ber of essential and supplemental criteria (Table 1) [14,15].
For SIADH, but also for hyponatraemia in general, it is
important to first establish that one is truly dealing with
hypotonic hyponatraemia by finding a low serum tonicity.
Tonicity or ‘effective osmolality’ is the measured osmo-
lality minus serum urea (and alcohol if present). Pseudo-
hyponatraemia still exists, even after the introduction of
ion-selective electrodes and may occur in the setting of
high triglycerides, total protein or cholesterol [16]. In pseu-
dohyponatraemia, the measured osmolality will be normal.
Hyperglycaemia-induced hyponatraemia (often mistakenly
called pseudohyponatraemia) is the other condition to con-
sider (SNa drops ∼3 mmol/L for every 10 mmol/L rise in
glycaemia). It would be wise to always order serum osmo-
lality and glucose together in patients with hyponatraemia
[12].
Once hypotonic hyponatraemia has been established and
the patient has a relatively high urine sodium (> 40mmol/L)
and osmolality (> 100 mOsm/kg, but usually > serum os-
molality) SIADH should be considered (Tables 1 and 2).
Euvolaemia is an essential requirement, but the clinical as-
sessment of the extracellular fluid volume has been shown
to present frequent difficulty [17,18]. The assessment of
fluid volume status is easy in patients who are frankly
hyper- or hypovolaemic. Hypovolaemia means extracellu-
lar fluid volume contraction and may occur after vomiting,
diarrhoea or overly ambitious use of diuretics, for exam-
ple in essential hypertension. It is characterized by ortho-
static hypotension, tachycardia, a flat jugular venous pres-
sure and often a low urinary sodium concentration (< 10–
20 mmol/L in the absence of diuretics). Patients with hy-
pervolaemic hyponatraemia usually present with peripheral
oedema or ascites, low normal or low blood pressure, and a
low urinary sodium concentration (<10–20 mmol/L in the
absence of diuretics) and typically have a compatible his-
tory of congestive heart failure or liver cirrhosis. However,
in doubtful cases, we believe that the bedside assessment
of the extracellular fluid volume should not be a decisive
parameter, as is unfortunately still the case in the majority
of clinical diagnostic algorithms [19].
According to the criteria (Table 1), diuretic use (espe-
cially thiazides), hypothyroidism and adrenal insufficiency
should be excluded prior to diagnosing SIADH [14,15]. The
first two requirements may be less stringent than previously
thought. A recent study indicates that it is possible to di-
agnose SIADH in patients on diuretics (thiazides or loop
diuretics) [20]. In such a setting the use of the fractional
uric acid excretion (≥12%) was of particular help to the
authors in diagnosing SIADH and this did not apply in the
same manner to the serum uric acid [20]. For calculating
the fractional uric acid excretion, uric acid and creatinine
should be measured in serum and a spot urine sample, both
collected at around the same time. The fractional uric acid
excretion is then calculated as (urine uric acid × serum
creatinine)/(serum uric acid × urine creatinine) × 100.
The relationship between hypothyroidism and hypona-
traemia was recently dismissed as an ‘old wives’ tale’
[21]. Although Warner et al. showed a statistical associa-
tion between hyponatraemia and hypothyroidism (for every
10 mU/L rise in thyroid-stimulating hormone, SNa de-
creased 0.14 mmol/L) [22], the clinical relevance of this
association is obviously minute. If the relationship does ex-
ist, it probably applies to severe myxoedema in which a low
cardiac output and/or a low glomerular filtration rate may
contribute to hyponatraemia [23].
Adrenal insufficiency is probably the most important
disorder to exclude before diagnosing SIADH. Although
SIADH is more common than adrenal insufficiency, the
consequences can be grave when adrenal insufficiency is
missed [24]. Adrenal insufficiency can have an atypical
presentation and Soule proposed to add Addison’s disease
to the list of ‘great mimickers in medicine’ [25]. Indeed,
we recently reported two patients with primary adrenal in-
sufficiency who had severe hyponatraemia, but no hyper-
kalaemia, orthostatic hypotension, metabolic acidosis, hy-
poglycaemia, anaemia or eosinophilia [26]. Both caseswere
first ‘diagnosed’ as SIADH, and only after fluid restriction
and isotonic saline-produced little response, adrenal func-
tion tests were carried out. Random cortisol levels between
100 and 500 nmol/L do still not exclude adrenal insuffi-
ciency fully [27]. Therefore, the response to a high (250μg)
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Table 3. Causes of SIADH
Malignancy Lung disease CNS disease Drugs Miscellaneous
Lung cancer (small Infections (bacterial, Infections Antiepileptics Idiopathic
cell, mesothelioma) viral, tuberculosis, (meningitis, Antidepressants Transient (nausea,
Oropharynx abscess) encephalitis, AIDS, (mainly SSRI’s) pain, stress)
GI-tract (stomach, Cystic fibrosis abscess) Antipsychotics Hereditary
duodenum, Status asthmaticus Stroke (CVA, Anaesthetics Exercise associated
pancreas) subarachnoid, Chemotherapy
Genitourinary tract subdural) (ifosfamide,
Endocrine thymoma Hydrocephalus cylcofosfamide,
Lymphomas Brain tumour vincristine)
Sarcomas (Ewing) Head trauma AVP analogues
Multiple sclerosis MDMA (‘Ecstasy’)
Guillain–Barre´
syndrome
Shy–Drager syndrome
Lewy body dementia
Adapted from Ellison and Berl [1]. The most common causes are underlined.
AIDS, acquired immunodeficiency syndrome; AVP, arginine vasopressin; CNS, central nervous system; CVA, cerebrovascular accident; GI, gastroin-
testinal; MDMA, 3,4-methylenedioxymethamphetamine; SSRI, selective serotonin reuptake inhibitors.
or low (1μg/1.73m2) dose of synthetic adrenocorticotropic
hormone (ACTH) is a superior test [28]. There should be
a low threshold for performing this test in patients with
hyponatraemia and a high urine sodium (>40 mmol/L) and
osmolality (>100 mOsm/kg, usually > serum osmolality).
The measurement of ACTH is also useful (high in primary
adrenal insufficiency, low in secondary or tertiary adrenal
insufficiency), but it is usually not available rapidly.
In practice, it is often worthwhile to use the response
to ‘therapy’ in the diagnosis of SIADH (Table 1). A com-
mon approach is to assess the response in SNa to isotonic
saline, which should rise in hypovolaemic hyponatraemia.
However, two important caveats should bementioned. First,
isotonic saline may aggravate SIADH, especially when the
tonicity of the urine is much larger than the infusate. Sec-
ondly, in hypovolaemic hyponatraemia, SNa may rise uncon-
trollably when the hypovolaemic stimulus for vasopressin
release abates [29]. If SIADH is established, but its patho-
physiology remains unclear and there is little or no response
to fluid restriction, a water-loading test could be of use.
Namely, if > 80% of a water load (20 mL/kg) is excreted
within 4 h after administration, a reset osmostat may be
present [30]. We recently used this approach to diagnose
reset osmostat in a patient with chronic hyponatraemia and
dementia with Lewy bodies [31]. However, one should be
extremely cautious to give a water load in other forms of
SIADH, because it may aggravate hyponatraemia.
The causes of SIADH are usually classified into five
major categories, including pulmonary disorders, malig-
nancy, central nervous system disorders, drugs and a mis-
cellaneous category, which includes idiopathic, transient
and hereditary causes (Table 3) [1]. A more physiological
classification is based on the level of vasopressin and its
response to osmolality (Figure 1) [32].
Asymptomatic hyponatraemia is not
asymptomatic—the new concept
In 2006, Renneboog and colleagues published a landmark
study on the neurological symptoms in elderly patients
Fig. 1. Four types of SIADH. Type A is characterized by unregulated
secretion of vasopressin, type B by elevated basal secretion of vasopressin
despite normal regulation by osmolality, type C by a ‘reset osmostat’ and
type D by undetectable vasopressin levels (these patients may have a gain
of function mutation of the V2-receptor). Especially for types C and D,
the term syndrome of inappropriate antidiuresis may be more appropriate.
According to present understanding, typeC andDpatientsmaynot respond
to vasopressin-receptor antagonists. The shaded area represents the normal
response showing a rise in vasopressin secretion with increasing serum
sodium concentrations. Adapted and reprinted from [32], Copyright 2006,
with permission from Elsevier.
with chronic and supposedly asymptomatic hyponatraemia
[10]. They conducted a matched case-control study in
which 122 patients with chronic hyponatraemia (SNa 126±
5 mmol/L) were compared to 244 controls. Patients with
congestive heart failure, liver cirrhosis and nephrotic syn-
drome as well as patients with acute hyponatraemia (poly-
dipsia and/or seizures) were excluded from the study. The
pathogenesis of hyponatraemia, as assessed by the response
to 2 L of isotonic saline, was SIADH (approximately half of
the patients), diuretic-induced hyponatraemia and salt de-
pletion. Hyponatraemic cases had had falls approximately
four times more often than controls (21% versus 5%).
However, they did not have more acute illnesses, chronic
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Fig. 2. Gait pattern in the same patient during and after correction of chronic hyponatraemia. Patient is walking from right to left. The arrow depicts an
irregular path of the centre of pressure. Tandem gait parameters were analysed with a pressure-sensitive calibrated platform that evaluates the patient’s
balance performance on the basis of the recorded displacement of the centre of pressure (i.e. the projection of the centre of gravity on the ground).
Adapted and reprinted from [10], Copyright 2006, with permission from Elsevier.
conditions, polypharmacy, central nervous system drugs, or
vasodilators. Surprisingly, the frequency of falls was sim-
ilar in patients with mild hyponatraemia (19% with SNa
130–132 mmol/L) compared to those with more severe hy-
ponatraemia (22% with SNa 115–117 mmol/L). To analyse
the mechanism of the falls, 16 similar elderly patients with
hyponatraemia (SNa 128 ± 3 mmol/L) were subjected to
formal neurocognitive testing (the tandem eyes open test
and eight visual and auditory attention tests) during hy-
ponatraemia and normonatraemia. These tests were also
performed in healthy volunteers with and without the con-
sumption of alcohol (blood alcohol concentration 0.6 ±
0.2 g/L). The degree of unsteadiness of the gait (as mea-
sured by a pressure-sensitive calibrated platform) was sig-
nificantly greater in patients while hyponatraemic as com-
pared to normonatraemic (Figure 2). With regard to atten-
tion tests, both the mean response latency and the total
number of errors were significantly greater during hypona-
traemia than in normonatraemia. A blood alcohol level of
0.6 g/L induced similar but lesser changes than hypona-
traemia. In a follow-up study, it was demonstrated that mild
hyponatraemia (SNa 131 ± 3 mmol/L) was also associated
with bone fracture in ambulatory elderly [33].
The Renneboog study should change our concept of
chronic ‘asymptomatic’ hyponatraemia dismissing it as a
benign condition. Currently, chronic hyponatraemia, which
is often due to SIADH, is accepted as a possible harm-
less complication of the underlying disease or treatment.
The possibility to relieve subtle but important neurological
symptoms by avoidance of hyponatraemia warrants consid-
eration. Falls and fractures are a public health concern, and
the potential to prevent these could have a great impact on
morbidity and mortality. Similar reasoning would apply to
an increased error rate in these patients (e.g. being confused
about one’s medication, switching the gas off in the kitchen
or leaving the door open when going out of the house).
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The good news is that the neurological signs in the
Renneboog-study were reversible after correction of hy-
ponatraemia [10]. They cite one intriguing case report to
explain their findings. This report demonstrated a phe-
nomenon of nerve conduction slowing, which was present
during hyponatraemia and resolved thereafter [34]. The au-
thors speculate that the extracellular sodium concentration
plays a role in nerve impulse generation. Hyponatraemia
would then lead to a lower electrochemical gradient of
sodium, and thus to a weaker sodium current during de-
polarization. If so, nerve conduction slowing represents a
new neurological manifestation of hyponatraemia.
How to improve the future management of
hyponatraemia
When formulating strategies to improve the management of
hyponatraemia, a number of common sense options come
tomind first. To name a few: better adherence to guidelines,
more precise application of the criteria for SIADH, better
analysis which predisposing factors for hyponatraemia are
present, earlier recognition of hospital-acquired hypona-
traemia, implementation of hospital warning systems and
physician education [6,8,11–13,19,35]. A sound diagnos-
tic approach to hyponatraemia in general is important to
identify patients with definite SIADH, who may then be
suitable for the appropriate treatment. We suggest that cur-
rently only SIADH patients with chronic hyponatraemia in
the range of 120–132 mmol/L are to be considered poten-
tial candidates for vasopressin-receptor antagonists. There
is too little experience with vaptans in SNa < 120 mmol/L,
whereas SNa between 133 and 135 mmol/L is often not
reproducible or represents a lab error.
Will vasopressin-receptor antagonists improve the out-
come of SIADH? Mortality will probably be a difficult
parameter to use, because the highest mortality rates are
seen in patients with hyponatraemia due to advanced heart
or liver disease and are usually ascribed to the severity of
the disease. A complicating factor is that few studies have
looked at SIADH only—the majority studied a mix of hy-
ponatraemic disorders [36]. Other outcome parameters of
morbidity may be more achievable, including a reduction
in the length of hospital stay, neurological improvement
and quality of life once fluid restriction has been lifted.
This will probably also lead to a change of perspective for
physicians, who often see chronic hyponatraemia as be-
nign. Physicians should begin to envision a hyponatraemic
patient to have a mental status that is like that of a normal
person who ingested a considerable amount of alcohol. The
fact that attention deficits in patients with hyponatraemia
were identified only recently suggests that we generally
overlook the mental impairments caused by hyponatraemia
in our patients, even though they are clearly important in
everyday life.
The question remains whether vasopressin-receptor an-
tagonists are superior to the traditional therapies for
SIADH. This may require head-to-head trials (for more
details, see the next article by Zietse et al.). Our case stud-
ies in the final article of this supplement illustrate some of
the current challenges of SIADH (van der Lubbe et al.).
Most physicians will agree that fluid restriction, the usual
treatment for SIADH, is cumbersome and stressful for both
patient and physician. Continuous fluid restriction in pa-
tients who have a tendency to develop hyponatraemia due
to chronic conditions or lifelong drug therapy is difficult to
maintain. In addition, these patients have a permanent risk
of worsening hyponatraemia, for example when they do
drink more, or when a second insult occurs (vomiting, diar-
rhoea, new drug, pneumonia). Similarly, as was illustrated
by the studies on hyponatraemia, hospitalization introduces
many factors (e.g., pain, nausea, drugs) that increase vaso-
pressin, some of which are unavoidable. These situations,
in combination with the insight that chronic hyponatraemia
is not benign, may suggest more stringent indications for
treatment of hyponatraemia, including with vasopressin-
receptor antagonists. Now that the vasopressin-receptor an-
tagonists are ‘out there’, it will be interesting to see how
popular they will become in the management of hypona-
traemia secondary to SIADH.
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